Psoriaziste sekukinumab: Tek merkez deneyimi

Acer, Ersoy; Kaya Erdogan, Hilal; Saracoglu, Zeynep Nurhan; Bilgin, Muzaffer; Agaoglu, Esra

doi:10.4274/turkderm.galenos.2021.75046

Psoriaziste sekukinumab: Tek merkez deneyimi

Esra Ağaoğlu, (Kars Harakani State Hospital, Clinic of Dermatology, Kars, Türkiye)

Hilal Kaya ERDOĞAN, (Eskişehir Osmangazi University Faculty of Medicine, Department of Biostatistics, Eskişehir, Türkiye)

Ersoy Acer, (Eskişehir Osmangazi University Faculty of Medicine, Department of Dermatology, Eskişehir, Türkiye)

Zeynep SARAÇOĞLU, (Eskişehir Osmangazi University Faculty of Medicine, Department of Dermatology, Eskişehir, Türkiye)

Muzaffer BİLGİN (Eskişehir Osmangazi University Faculty of Medicine, Department of Dermatology, Eskişehir, Türkiye)

Türkderm Türk deri hastalıkları ve frengi arşivi

30 2

Yıl: 2021 Cilt: 55 Sayı: 3 Sayfa Aralığı: 125 - 129 Metin Dili: Türkçe DOI: 10.4274/turkderm.galenos.2021.75046 İndeks Tarihi: 21-05-2022

Psoriaziste sekukinumab: Tek merkez deneyimi

Öz:

Amaç: Birçok randomize klinik çalışma, orta-şiddetli psoriazisin sistemik tedavisinde sekukinumabın etkinliği ve güvenilirliğini ortaya koyarken, gerçek yaşam verileri sınırlıdır. Çalışmamızın amacı psoriaziste sekukinumabın etkinliği ve güvenilirliğini değerlendirmektir. Gereç ve Yöntem: Çalışmada sekukinumab tedavisi alan 32 hasta retrospektif olarak incelendi. Sekukinumabın etkinliği tedavinin 16., 24. ve 36. haftalarında psoriazis alan şiddet indeksi (PAŞİ) 50, 75, 90 yanıt oranları ile değerlendirildi. Sekukinumab tedavisinin yan etkileri kaydedildi. Bulgular: Otuz iki hastanın sekukinumab tedavisi öncesi PAŞİ ortalaması 12,38±6,49 olup tedavinin 16., 24. ve 36. haftalarında sırasıyla; 1,96, 1,85 ve 3,1’e geriledi. Tedavinin 16. haftasında hastaların %83,3’ü PAŞİ 50’ye ulaşırken %70’inde PAŞİ 75 ve %50’sinde PAŞİ 90 yanıt oranları elde edildi. Tedavinin 16., 24. ve 36. haftalarında, PAŞİ 50, 75 ve 90 yanıtları, biyolojik-naif hastalarda, biyolojik-naif olmayanlara göre daha yüksekti, ancak istatistiksel olarak anlamlı bir fark saptanamadı (p>0,05). Beş (%15,6) hastada yetersiz klinik yanıt, 2 (%6,2) hastada ise tedaviye bağlı yan etkiler nedeniyle toplam 7 (%21,9) hastada tedavi kesildi. Dört (%12,5) hastada görülen oral kandidiyazis sekukinumaba bağlı en sık yan etki olarak kaydedildi Sonuç: Sekukinumab, orta-şiddetli psoriazis hastalarında etkili ve güvenli bir tedavi seçeneğidir. Sekukinumabın gerçek yaşam verisi olarak etkinliği biyolojik-naif hastalarda daha yüksek olabilir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Ayala-Fontánez N, Soler DC, McCormick TS: Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl) 2016;6:7-32.
2. Cai Y, Fleming C, Yan J: New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol 2012;9:302-9.
3. Silfvast-Kaiser A, Paek SY, Menter A: Anti-IL17 therapies for psoriasis. Expert Opin Biol Ther 2019;19:45-54.
4. Kormeili T, Lowe N, Yamauchi P: Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; US experiences. Br J Dermatol 2004;151:3-15.
5. Sivamani RK, Correa G, Ono Y, Bowen MP, Raychaudhuri SP, Maverakis E: Biological therapy of psoriasis. Indian J Dermatol 2010;55:161-70.
6. Frieder J, Kivelevitch D, Menter A: Secukinumab: A review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis 2018;9:5-21.
7. Langley RG, Krueger GG, Griffiths CE: Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64(Suppl2):18-23.
8. Blauvelt A, Reich K, Tsai TF, et al: Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. J Am Acad Dermatol 2017;76:60-9.e9.
9. Paul C, Lacour JP, Tedremets L, et al: Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol 2015;29:1082- 90.
10. Yıldırım FE, Hapa FA: Clinical efficacy and safety of secukinumab for psoriasis in a real-world setting in Turkey. J Dermatolog Treat 2020;1-7.
11. Galuzzo M, D’Adamio S, Silvaggio D, Lombardo P, Bianchi L, Talamonti M: In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-tosevere plaque psoriasis. Expert Opin Biol Ther 2020;20:173-82.
12. Rompoti N, Katsimbri P, Kokkalis G, et al: Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104 week clinical study. Dermatol Ther 2019;32: e13006.
13. Özçelik S, Kılıç FA, Başara R: Retrospective analysis of patients with psoriasis receiving biological therapy: Real-life data. Dermatol Ther 2020;33:e14336.
14. Özkur E, Kıvanç Altunay İ, Oğuz Topal İ, et al: Switching Biologics in the Treatment of Psoriasis: A Multicenter Experience. Dermatology 2021;237:22- 30.
15. Topaloğlu Demir F, Özkök Akbulut T, Kıvanç Altunay I, et al: Evaluation of the adverse effects of biological agents used in the treatment of psoriasis: A multicenter retrospective cohort study. Dermatol Ther 2020;33:e14216.
16. Fujita H, Ohtsukı M, Morita A, et al: Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real-world evidence in Japan. J Dermatol 2021;48:175-83.
17. Rompoti N, Sidiropoulou P, Panagakis P, et al: Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response. J Eur Acad Venereol 2020;34:1240-7.
18. Notario J, Deza G, Vilarrasa E, et al: Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. J Dermatolog Treat 2019;30:424-9.
19. Galluzzo M, Talamonti M, De Simone C, et al: Secukinumab in moderate-tosevere plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther 2018;18:727-35.
20. Momose M, Asahina A, Umezawa Y, Nakagawa H: Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience. J Dermatol 2018;45:318-21.
21. Chiricozzi A, Balato A, Conrad C, et al: Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a european, multicentric, retrospective, real-world study. J Dermatolog Treat 2020;31:476-83.
22. Ger TY, Huang YH, Hui RC, Tsai TF, Chiu HY: Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement. Ther Adv Chronic Dis 2019;10:2040622319843756.
23. Georgakopoulos JR, Ighani A, Zhou LL, Yeung J: Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two realworld Canadian dermatology clinics: a multicenter retrospective study. J Eur Acad Dermatol Venereol 2018;32:e32-4.
24. Megna M, Camela E, Cinelli E, Fabbrocini G: Real-life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol 2020;45:848-52.
25. Kammüller M, Tsai TF, Griffiths CE, et al: Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunology 2017;6:e152.
26. Gisondi P, Cotena C, Tessari G, Girolomoni G: Anti-tumour necrosis factoralpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008;22:341-4.
27. Renzo LD, Saraceno R, Schipani C, et al: Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-alpha treatment. Dermatol Ther 2011;24:446-51.
28. Tan E, Baker C, Foley P: Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis. Australas J Dermatol 2013;54:259-63.
29. Takamura S, Takahashi A, Inoue Y, Teraki Y: Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis. J Dermatol 2018;45:1130-4.
30. Dastoli S, Iannone LF, Bennardo L, et al: A Rare Case of Drug-Induced Erectile Dysfunction With Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report. Curr Drug Saf 2020;15:69-72.

APA	Agaoglu E, Kaya Erdogan H, Acer E, Saracoglu Z, Bilgin M (2021). Psoriaziste sekukinumab: Tek merkez deneyimi. , 125 - 129. 10.4274/turkderm.galenos.2021.75046
Chicago	Agaoglu Esra,Kaya Erdogan Hilal,Acer Ersoy,Saracoglu Zeynep Nurhan,Bilgin Muzaffer Psoriaziste sekukinumab: Tek merkez deneyimi. (2021): 125 - 129. 10.4274/turkderm.galenos.2021.75046
MLA	Agaoglu Esra,Kaya Erdogan Hilal,Acer Ersoy,Saracoglu Zeynep Nurhan,Bilgin Muzaffer Psoriaziste sekukinumab: Tek merkez deneyimi. , 2021, ss.125 - 129. 10.4274/turkderm.galenos.2021.75046
AMA	Agaoglu E,Kaya Erdogan H,Acer E,Saracoglu Z,Bilgin M Psoriaziste sekukinumab: Tek merkez deneyimi. . 2021; 125 - 129. 10.4274/turkderm.galenos.2021.75046
Vancouver	Agaoglu E,Kaya Erdogan H,Acer E,Saracoglu Z,Bilgin M Psoriaziste sekukinumab: Tek merkez deneyimi. . 2021; 125 - 129. 10.4274/turkderm.galenos.2021.75046
IEEE	Agaoglu E,Kaya Erdogan H,Acer E,Saracoglu Z,Bilgin M "Psoriaziste sekukinumab: Tek merkez deneyimi." , ss.125 - 129, 2021. 10.4274/turkderm.galenos.2021.75046
ISNAD	Agaoglu, Esra vd. "Psoriaziste sekukinumab: Tek merkez deneyimi". (2021), 125-129. https://doi.org/10.4274/turkderm.galenos.2021.75046

APA	Agaoglu E, Kaya Erdogan H, Acer E, Saracoglu Z, Bilgin M (2021). Psoriaziste sekukinumab: Tek merkez deneyimi. Türkderm Türk deri hastalıkları ve frengi arşivi, 55(3), 125 - 129. 10.4274/turkderm.galenos.2021.75046
Chicago	Agaoglu Esra,Kaya Erdogan Hilal,Acer Ersoy,Saracoglu Zeynep Nurhan,Bilgin Muzaffer Psoriaziste sekukinumab: Tek merkez deneyimi. Türkderm Türk deri hastalıkları ve frengi arşivi 55, no.3 (2021): 125 - 129. 10.4274/turkderm.galenos.2021.75046
MLA	Agaoglu Esra,Kaya Erdogan Hilal,Acer Ersoy,Saracoglu Zeynep Nurhan,Bilgin Muzaffer Psoriaziste sekukinumab: Tek merkez deneyimi. Türkderm Türk deri hastalıkları ve frengi arşivi, vol.55, no.3, 2021, ss.125 - 129. 10.4274/turkderm.galenos.2021.75046
AMA	Agaoglu E,Kaya Erdogan H,Acer E,Saracoglu Z,Bilgin M Psoriaziste sekukinumab: Tek merkez deneyimi. Türkderm Türk deri hastalıkları ve frengi arşivi. 2021; 55(3): 125 - 129. 10.4274/turkderm.galenos.2021.75046
Vancouver	Agaoglu E,Kaya Erdogan H,Acer E,Saracoglu Z,Bilgin M Psoriaziste sekukinumab: Tek merkez deneyimi. Türkderm Türk deri hastalıkları ve frengi arşivi. 2021; 55(3): 125 - 129. 10.4274/turkderm.galenos.2021.75046
IEEE	Agaoglu E,Kaya Erdogan H,Acer E,Saracoglu Z,Bilgin M "Psoriaziste sekukinumab: Tek merkez deneyimi." Türkderm Türk deri hastalıkları ve frengi arşivi, 55, ss.125 - 129, 2021. 10.4274/turkderm.galenos.2021.75046
ISNAD	Agaoglu, Esra vd. "Psoriaziste sekukinumab: Tek merkez deneyimi". Türkderm Türk deri hastalıkları ve frengi arşivi 55/3 (2021), 125-129. https://doi.org/10.4274/turkderm.galenos.2021.75046